On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation

Xixi Wang,Yanfei Wang,Jing Chen,Qinyao Wang,Zhongjian Liu,Yijie Yin,Tonghua Yang,Tao Shen,Yalian Sa
DOI: https://doi.org/10.1038/s41598-024-60859-0
IF: 4.6
2024-05-04
Scientific Reports
Abstract:Wogonin is a natural flavone compound from the plant Scutellaria baicalensis, which has a variety of pharmacological activities such as anti-cancer, anti-virus, anti-inflammatory, and immune regulation. However, the potential mechanism of wogonin remains unknown. This study was to confirm the molecular mechanism of wogonin for acute monocytic leukemia treatment, known as AML-M5. The potential action targets between wogonin and acute monocytic leukemia were predicted from databases. The compound-target-pathway network and protein-protein interaction network (PPI) were constructed. The enrichment analysis of related targets and molecular docking were performed. The network pharmacological results of wogonin for AML-M5 treatment were verified using the THP-1 cell line. 71 target genes of wogonin associated with AML-M5 were found. The key genes TP53, SRC, AKT1, RELA, HSP90AA1, JUN, PIK3R1, and CCND1 were preliminarily found to be the potential central targets of wogonin for AML-M5 treatment. The PPI network analysis, GO analysis and KEGG pathway enrichment analysis demonstrated that the PI3K/AKT signaling pathway was the significant pathway in the wogonin for AML-M5 treatment. The antiproliferative effects of wogonin on THP-1 cells of AML-M5 presented a dose-dependent and time-dependent manner, inducing apoptosis, blocking the cell cycle at the G2/M phase, decreasing the expressions of CCND1, CDK2, and CyclinA2 mRNA, as well as AKT and p-AKT proteins. The mechanisms of wogonin on AML-M5 treatment may be associated with inhibiting cell proliferation and regulating the cell cycle via the PI3K/AKT signaling pathway.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem this paper attempts to address is the therapeutic mechanism of wogonin on acute monocytic leukemia (AML-M5). Specifically, the study aims to predict the potential targets of wogonin in AML-M5 through network pharmacology, bioinformatics, and molecular docking techniques, and to validate these predictions through in vitro experiments. ### Main Research Content: 1. **Background Introduction**: - Acute monocytic leukemia (AML-M5) is a subtype of acute myeloid leukemia characterized by the predominance of monoblasts and promonocytes. Despite some progress in chemotherapy and biological targeted therapy, the 5-year survival rate remains unsatisfactory. - Wogonin is a natural flavonoid compound extracted from Scutellaria baicalensis, with various pharmacological activities such as anti-cancer, anti-viral, anti-inflammatory, and immunomodulatory effects. - The study hypothesizes that wogonin may be a promising adjuvant candidate for the treatment of AML-M5. 2. **Research Methods**: - **Network Pharmacology**: Potential targets of wogonin were obtained from databases and intersected with AML-M5 related targets to construct a compound-target-pathway network diagram. - **Protein-Protein Interaction (PPI) Network Analysis**: A PPI network was constructed using the String platform, and core targets were screened. - **GO and KEGG Pathway Enrichment Analysis**: Functional annotation and pathway enrichment analysis were performed on the related targets to identify key signaling pathways. - **Molecular Docking**: The binding modes of wogonin with core targets were analyzed using AutoDockTools software. - **In Vitro Experimental Validation**: The pharmacological effects of wogonin in THP-1 cells were validated using CCK-8 assay, flow cytometry, and Western Blot techniques. 3. **Main Findings**: - **Network Pharmacology and PPI Network Analysis**: Identified 71 wogonin target genes related to AML-M5, with TP53, SRC, AKT1, RELA, HSP90AA1, JUN, PIK3R1, and CCND1 preliminarily identified as core targets. - **GO and KEGG Pathway Analysis**: Results indicated that the PI3K/AKT signaling pathway is a key pathway for wogonin in the treatment of AML-M5. - **Molecular Docking**: Wogonin showed low binding energy with core targets, particularly with AKT1, which had a binding energy of -7.34 kcal/mol. - **In Vitro Experimental Validation**: Wogonin exhibited dose-dependent and time-dependent anti-proliferative effects in THP-1 cells, induced apoptosis, arrested the cell cycle at the G2/M phase, and reduced the mRNA expression of CCND1, CDK2, and CyclinA2, as well as the protein expression of AKT and p-AKT. ### Conclusion: This study, through network pharmacology and in vitro experiments, reveals that wogonin exerts therapeutic effects on AML-M5 by inhibiting the PI3K/AKT signaling pathway, suppressing cell proliferation, inducing apoptosis, and arresting the cell cycle. These findings provide a theoretical basis for the clinical application of wogonin in the treatment of AML-M5.